Theseus Pharmaceuticals Inc (THRX)

Name: Theseus Pharmaceuticals Inc (THRX) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Theseus Pharmaceuticals Inc (THRX)

Stock Card

$4.06

$0.00 (0.00%)

As on 23-Feb-2024 09:30EDT

Market cap

$181 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

P/B Ratio

0.8

Div. Yield

0 %

Theseus Pharmaceuticals Inc (THRX) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 4.06 High: 4.06

52 Week Range

Low: -- High: --

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$-43 Mln
ROE

-0.3 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

0.3
Debt to Equity

0
Book Value

$--
EPS

$-1.3
Face value

--
Shares outstanding

44,649,200

5 Years Aggregate

CFO

$-119.43 Mln

EBITDA

$-93.14 Mln

Net Profit

$-150.18 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Theseus Pharmaceuticals Inc (THRX)	0.2	1.8	17.7	-58.5	--	--	--
BSE Sensex^*	-8.8	0.6	1.8	-4.4	6.0	6.6	10.8
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 23-Feb-2024 | *As on 28-Aug-2026 | #As on 26-Oct-2023

Company	2023	2022
Theseus Pharmaceuticals Inc (THRX)	-18.7	-60.7
S&P Small-Cap 600	13.9	-17.4
BSE Sensex	18.7	4.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
Theseus Pharmaceuticals Inc (THRX)	4.1	181.3	0.0	-55.9	--	-23.8	--	0.8
Freeline TherapeuticsÂ Holdings Plc (FRLN)	6.5	28.2	0.6	-74.1	-11,456.1	-179.7	--	0.9

Shareholding Pattern

View Details

About Theseus Pharmaceuticals Inc (THRX)

Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the... treatment of gastrointestinal stromal tumors. The company also develops THE-349, a fourth-generation selective epidermal growth factor receptor inhibitor to address C797X-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts. As of February 14, 2024, Theseus Pharmaceuticals, Inc. operates as a subsidiary of Concentra Biosciences, LLC. Read more

Co-Founder & Chairman

Dr. Iain D. Dukes DPHIL, M.A.
Co-Founder & Chairman

Dr. Iain D. Dukes DPHIL, M.A.
Headquarters

Cambridge, MA
Website

https://theseusrx.com

FAQs for Theseus Pharmaceuticals Inc (THRX)

What is the current share price of Theseus Pharmaceuticals Inc (THRX) Today?

The share price of Theseus Pharmaceuticals Inc (THRX) is $4.06 (NASDAQ) as of 23-Feb-2024 09:30 EDT. Theseus Pharmaceuticals Inc (THRX) has given a return of -58.53% in the last 1 years.

What is the current PB & PE ratio of Theseus Pharmaceuticals Inc (THRX)?

Since, TTM earnings of Theseus Pharmaceuticals Inc (THRX) is negative, P/E ratio is not available.
The P/B ratio of Theseus Pharmaceuticals Inc (THRX) is 0.81 times as on 27-Feb-2024, a 85 discount to its peers’ median range of 5.35 times.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2022	-4.09	0.93
2021	-16.66	1.85
2020	--	--
2019	--	--
2022	-4.09	0.93

What is the 52 Week High and Low of Theseus Pharmaceuticals Inc (THRX)?

The 52-week high and low of Theseus Pharmaceuticals Inc (THRX) are Rs -- and Rs -- as of 29-Aug-2026.

What is the market cap of Theseus Pharmaceuticals Inc (THRX)?

Theseus Pharmaceuticals Inc (THRX) has a market capitalisation of $ 181 Mln as on 27-Feb-2024. As per SEBI classification, it is a Small Cap company.

Should I invest in Theseus Pharmaceuticals Inc (THRX)?

Before investing in Theseus Pharmaceuticals Inc (THRX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.